UNIGE document Scientific Article
previous document  unige:2048  next document
add to browser collection

Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy

Sommer, W H.
Gachoud, D.
Keta, A.
Abou-Hajar, A.
Dudler, J.
Aujesky, D.
Published in Scandinavian Journal of Rheumatology. 2008, vol. 37, no. 4, p. 306-9
Abstract We report the case of a patient receiving subcutaneous methotrexate (MTX) treatment for rheumatoid arthritis (RA) who developed a complex pattern of neurological and pulmonary symptoms. Fluctuant dysarthria, magnetic gait, weakness and dysmetria of the lower limbs, as well as symptoms and signs consistent with a diagnosis of pneumonitis started within 6 weeks of initiating MTX treatment and slowly resolved after its discontinuation. This case highlights the fact that even the relatively low doses of MTX in the therapy of RA can produce neurotoxicity, which can become manifest in a broad range of symptoms.
Keywords Aged, 80 and overArthritis, Rheumatoid/drug therapyFemaleHumansImmunosuppressive Agents/administration & dosage/adverse effectsInjections, SubcutaneousMethotrexate/administration & dosage/adverse effectsNeurotoxicity Syndromes/etiologyPneumonia/chemically induced
PMID: 18612932
Full text
(ISO format)
SOMMER, W H. et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. In: Scandinavian Journal of Rheumatology, 2008, vol. 37, n° 4, p. 306-9. doi: 10.1080/03009740801908001 https://archive-ouverte.unige.ch/unige:2048

387 hits



Deposited on : 2009-06-16

Export document
Format :
Citation style :